GP2 (NCT06719583)
Identify genes influencing Parkinson progression
- Trial ID
- NCT06719583
- Official Title
- Black and African Americans Connections to Parkinson's Disease (BLAAC PD) A Project of the Global Parkinson's Genetics Program (GP2)
- Study Acronym
- GP2
- Goal
- Identify genes influencing Parkinson progression
- Status
- RECRUITING
- Sponsor
- Michael J. Fox Foundation for Parkinson's Research
- Study Type
- OBSERVATIONAL
- Enrollment
- 2000 participants
- Conditions
- Parkinson Disease
Summary For Families
The project aims to find genetic factors that affect Parkinson's risk, symptoms, and progression in Black and African American people, a group that has been underrepresented in Parkinson's research. Participants share clinical information and provide DNA, commonly via a saliva sample, so researchers can look for genetic variants linked to disease features or treatment response; there are no drugs or devices given, and if you give saliva you should avoid food, drink, gum, tobacco, or smoking for 30 minutes beforehand. The study plans to enroll about 2,000 people who self-identify as Black or African American, with Parkinson's participants aged 18 or older who meet Movement Disorder Society diagnostic criteria, and control participants aged 50 or older with no personal or family history of Parkinson's or other neurodegenerative or psychiatric conditions, and all must be able to give informed consent.
Locations
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- University of Florida, Gainesville, Florida, United States
- Rush University, Chicago, Illinois, United States
- University of Chicago, Chicago, Illinois, United States
- Ochsner Clinic Foundation, New Orleans, Louisiana, United States
- Louisiana State University Health Sciences Center Shreveport, Shreveport, Louisiana, United States
- University of Maryland, Baltimore, Maryland, United States
- Kaiser Permanente Midatlantic States, Rockville, Maryland, United States
- Washington University in St. Louis, St Louis, Missouri, United States
- University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- University of Texas Health Science Center, Houston, Houston, Texas, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. The project aims to find genetic factors that affect Parkinson's risk, symptoms, and progression in Black and African American people, a group that has been underrepresented in Parkinson's research. Participants share clinical information and provide DNA, commonly via a saliva sample, so researchers can look for genetic variants linked to disease features or treatment response; there are no drugs or devices given, and if you give saliva you should avoid food, drink, gum, tobacco, or smoking for 30 minutes beforehand. The study plans to enroll about 2,000 people who self-identify as Black or African American, with Parkinson's participants aged 18 or older who meet Movement Disorder Society diagnostic criteria, and control participants aged 50 or older with no personal or family history of Parkinson's or other neurodegenerative or psychiatric conditions, and all must be able to give informed consent.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 12 locations.
- Does it cost anything to join?
- You are never charged a fee to join a legitimate clinical trial, and the study treatment and study-specific tests are provided by the trial sponsor at no charge. In the US, routine care you would receive anyway can still be billed to you or your insurance; coverage rules differ by country, and trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
- How long does the trial last?
- This trial is estimated to last approximately 7 years and 1 month.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- This is an observational study, so there is no placebo and no experimental treatment is assigned. Researchers observe and collect information while you continue your usual care.
- How many visits does this trial involve?
- You will attend one study visit.